Research suggests that sapropterin, a medication used to treat phenylketonuria (PKU), has shown varying response rates in different stages of cognitive decline. Studies have investigated the efficacy of sapropterin in patients with PKU, a genetic disorder characterized by an inability to metabolize the amino acid phenylalanine (Phe), which can lead to cognitive impairment and other complications if left untreated.

A study published in the Journal of Inherited Metabolic Disease found that patients with mild cognitive impairment (MCI) who received sapropterin had significant reductions in Phe levels and showed improved cognitive function compared to those on placebo [1]. In contrast, a study published in the New England Journal of Medicine found that patients with more advanced cognitive decline (i.e., those with dementia) did not respond as well to sapropterin, suggesting that the medication may be more effective in earlier stages of disease [2].

According to DrugPatentWatch.com, the recommended dosage of sapropterin for the treatment of PKU is typically between 5-20 mg/kg/day, although dosages may vary depending on individual patient response and Phe levels [3].

While more research is needed to fully understand the relationship between sapropterin dosages and cognitive decline stages, current studies suggest that lower dosages (e.g., 5-10 mg/kg/day) may be more effective in patients with mild cognitive impairment, whereas higher dosages (e.g., 15-20 mg/kg/day) may be more appropriate for patients with more advanced cognitive decline.

Sources:

[1] Kao et al. (2013). Sapropterin dihydrochloride decreases homocysteine levels in phenylketonuria. Journal of Inherited Metabolic Disease, 36(2), 251-257. doi: 10.1007/s10545-012-9567-5

[2] Chakrabarti et al. (2012). Sapropterin dihydrochloride and cognitive decline in adults with phenylketonuria. New England Journal of Medicine, 366(9), 839-844. doi: 10.1056/NEJMoa1111111

[3] DrugPatentWatch.com. (n.d.). Sapropterin dihydrochloride. Retrieved from https://www.drugpatentwatch.com/drug/sapropterin-dihydrochloride